<DOC>
	<DOCNO>NCT00003081</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining chemotherapy peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug kill tumor cell . Radiation therapy use high-energy x-rays damage tumor cell . PURPOSE : Phase I trial study effectiveness combination chemotherapy , peripheral stem cell transplantation , radiation therapy treat patient recurrent metastatic Ewing 's sarcoma , peripheral primitive neuroectodermal tumor , rhabdomyosarcoma .</brief_summary>
	<brief_title>Combination Chemotherapy , Peripheral Stem Cell Transplantation , Radiation Therapy Treating Patients With Ewing 's Sarcoma , Peripheral Primitive Neuroectodermal Tumor , Rhabdomyosarcoma</brief_title>
	<detailed_description>OBJECTIVES : I . Estimate maximum tolerate dose total bone marrow irradiation ( TMI ) administer plan consolidation utilize autologous peripheral blood stem cell support follow local radiotherapy ( indicate ) prior busulfan , melphalan , thiotepa . II . Examine efficacy dual transplant approach high-risk patient Ewing 's sarcoma , peripheral primitive neuroectodermal tumor , rhabdomyosarcoma first complete remission great . OUTLINE : This two part , radiation dose escalation study . Peripheral blood stem cell ( PBSC ) collect 5-6 daily injection G-CSF . The PBSC infuse two half . One half give chemotherapy half total marrow irradiation ( TMI ) . Transplant # 1 ( part one ) consist chemotherapy PBSC infusion . Busulfan ( BU ) administer orally every 6 hour 3 day total 12 dos day -8 , -7 -6 . Melphalan intravenously infuse 30 minute 2 day day -5 -4 . Thiotepa intravenously infuse 2 hour day -3 -2 . PBSC infuse day 0 , 36-48 hour completion chemotherapy . Patients consider local irradiation therapy transplant # 1 # 2 tissue limit irradiation dos bulk tumor site previously administer . The local irradiation give immediately prior TMI administration . Transplant # 2 start sometime day 60 120 transplant # 1 . For transplant # 2 , cohort 4 patient treat TMI twice day 5 day initial dose level day -5 -1 . TMI administer 30-40 minute . The second half PBSC infuse 1-24 hour follow last dose TMI . After treatment least 4 patient initial TMI dose level , dose level escalate absence toxicity . If dose limit toxicity ( DLT ) current group 4 patient , next cohort treat next high dose level . If 1 4 patient experience DLT , next cohort treat dose . If 1 DLT see among 8 patient treat dose , next cohort treat next high dose level . If 2 patient 8 experience DLT , dose identify maximum tolerate dose ( MTD ) . If 1 4 3 8 patient experience DLT dose level , next low dose level identify MTD . Each patient cohort observe minimum 28 day prior escalation high dose level . Tumor restaging occurs approximately 9 month initial transplant , 12 month annually thereafter . PROJECTED ACCRUAL : An expected 12-16 patient require complete study . Accrual last 3-4 year 4-5 patient per year .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Sarcoma , Ewing</mesh_term>
	<mesh_term>Neuroectodermal Tumors</mesh_term>
	<mesh_term>Neuroectodermal Tumors , Primitive</mesh_term>
	<mesh_term>Rhabdomyosarcoma</mesh_term>
	<mesh_term>Neuroectodermal Tumors , Primitive , Peripheral</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm recurrent metastatic Ewing 's sarcoma , peripheral primitive neuroectodermal tumor ( PNET ) Clinical Group IV rhabdomyosarcoma Complete remission good partial remission ( least 50 % reduction measurable tumor burden ) follow initial chemotherapy without surgery No primary CNS PNET PATIENT CHARACTERISTICS : Age : Under 50 Performance status : Karnofsky 70100 % Life expectancy : Greater 3 month Hematopoietic : Granulocyte count least 1,000/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin le 2.0 mg/dL Renal : Creatinine clearance great 50 % normal Pulmonary : LVEF great 41 % Other : HIV negative Not pregnant PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics Endocrine therapy : Not specify Radiotherapy : No prior dose limit irradiation organ site Surgery : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>recurrent childhood rhabdomyosarcoma</keyword>
	<keyword>recurrent adult soft tissue sarcoma</keyword>
	<keyword>adult rhabdomyosarcoma</keyword>
	<keyword>recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
</DOC>